Ireland - English - HPRA (Health Products Regulatory Authority)

neuraxpharm ireland limited - fingolimod - capsule, hard - 0.5 milligram(s) - fingolimod

Ireland - English - HPRA (Health Products Regulatory Authority)

msn labs europe limited - fingolimod - capsule, hard - fingolimod

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 50 mg - capsule - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; povidone; iron oxide red; mannitol; titanium dioxide; croscarmellose sodium; iron oxide black; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 37.5 mg - capsule - excipient ingredients: povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; microcrystalline cellulose; gelatin; mannitol; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 12.5 mg - capsule - excipient ingredients: titanium dioxide; povidone; microcrystalline cellulose; iron oxide red; gelatin; mannitol; magnesium stearate; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 25 mg - capsule - excipient ingredients: magnesium stearate; gelatin; croscarmellose sodium; mannitol; povidone; microcrystalline cellulose; iron oxide red; titanium dioxide; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 25 mg - capsule - excipient ingredients: gelatin; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; povidone; mannitol; titanium dioxide; iron oxide red; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 37.5 mg - capsule - excipient ingredients: povidone; gelatin; microcrystalline cellulose; magnesium stearate; mannitol; titanium dioxide; croscarmellose sodium; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 50 mg - capsule - excipient ingredients: gelatin; titanium dioxide; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; iron oxide red; povidone; mannitol; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 12.5 mg - capsule - excipient ingredients: magnesium stearate; mannitol; gelatin; iron oxide red; microcrystalline cellulose; povidone; croscarmellose sodium; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).